In accordance with the opinion that simultaneous targeting of multiple pathways involved in tumor progression will be required to treat cancer, we could hypothesize a future therapeutic use of 46F2SIP antibody in combination with immunocytokine L19-IL2 in EOC target therapy, in addition to standard therapeutic protocols [10]. Here, IL2 is linked to cancer.